Power Law company profile

Aiolos Bio

Biotech & Life Sciences · San Francisco, United States · Founded 2023 Unicorn

Revolutionizing the treatment landscape for respiratory disease and other immune conditions

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

5 investors on Aiolos Bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage

Sofinnova Investments

RA Capital Management

Forbion Capital Partners

Atlas Venture

Bain Capital Life Sciences

Global footprint

Where Aiolos Bio has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Market sentiment

What the market is saying about Aiolos Bio

An AI-synthesized read of the highest-engagement posts about Aiolos Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aiolos Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles